SCHEMBL350009

SCHEMBL350009

[NH]C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.65
TSHR P16473 1/20 0.65
CASP1 P29466 1/20 0.65
ALDH1A1 P00352 4/20 0.59
MAPK1 P28482 1/20 0.59
HIF1A Q16665 1/20 0.59
MAPT P10636 3/20 0.57
KDM4E B2RXH2 1/20 0.57
ERCC5 P28715 1/20 0.52
FEN1 P39748 1/20 0.52
SRD5A2 P31213 1/20 0.52
HSD17B10 Q99714 1/20 0.50
POLB P06746 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
THRB P10828 1/20 0.49
RECQL P46063 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970982 0.82 ALDH1A1 (0.65) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL195020 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL30185351 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL8065539 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL180845 0.81 SMN1; SMN2 (0.71) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL20512347 0.80 SMN1; SMN2 (0.63) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL5732135 0.79 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL19998346 0.79 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL107060 0.79 SMN1; SMN2 (0.68) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1
SCHEMBL111279 0.79 TSHR (1.00) SMN1; SMN2TSHRCASP1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase AXYS PHARMACEUTICALS, INC. (US) 2006-03-16 US claimed
EP-1472216-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE Axys Pharmaceuticals (US) 2004-11-03 EP claimed
WO-2003066579-A2 NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE AXYS PHARMACEUTICALS (US) 2003-08-14 WO claimed
US-6380247-B2 A WOOD PRESERVATIVE; POTENTIATION WHEN MIXED WITH AT LEAST ONE OF 3-BROMO-2,3-DIIODO-2-PROPENYL-ETHYLCARBAMATE, 3-IODO-2-PROPYNYLBUTYL-CARBAMATE AND 4-CHLOROPHENYL-3-IODOPROPARGYLFORMAL; MICROBIOCIDES SANKYO COMPANY, LIMITED (JP) 2002-04-30 US claimed
US-6005116-A HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA SANKYO COMPANY, LIMITED (JP) 1999-12-21 US claimed
EP-0885891-A1 ISOXAZOLE DERIVATIVES SANKYO COMPANY LIMITED (JP) 1998-12-23 EP claimed
US-9587129-B2 Ink composition and ink set SEIKO EPSON CORPORATION (JP) 2017-03-07 US disclosed
US-20160137859-A1 INK COMPOSITION AND INK SET SEIKO EPSON CORPORATION (JP) 2016-05-19 US disclosed
US-20160032125-A1 INK SET SEIKO EPSON CORPORATION (JP) 2016-02-04 US disclosed
EP-2977414-A1 INK SET Seiko Epson Corporation (JP) 2016-01-27 EP disclosed
EP-2489706-B1 Ink composition and ink jet recording method using the same SEIKO EPSON CORP (JP) 2015-03-04 EP disclosed
EP-2589631-B1 INK COMPOSITION, INKJET RECORDING METHOD AND COLORED BODY NIPPON KAYAKU KK (JP) 2014-08-20 EP disclosed
US-20140221369-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX, LLC (US) 2014-08-07 US disclosed
US-4281116-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1981-07-28 US disclosed
US-4260745-A 3-Halo cephalosporins ELI LILLY AND COMPANY (US) 1981-04-07 US disclosed
US-4252950-A ANTIBIOTICS, BACTERICIDES, FUNGICIDES ELI LILLY AND COMPANY (US) 1981-02-24 US disclosed
US-4208515-A 3-Halo cephalosporins ELI LILLY AND COMPANY (US) 1980-06-17 US disclosed
US-4064343-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1977-12-20 US disclosed
US-3985737-A ANTIBACTERIAL AGENTS ELI LILLY AND COMPANY (US) 1976-10-12 US disclosed
US-3962227-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221369-A1 5-DEUTERO-2,4-THIAZOLIDINEDIONE AND 5-DEUTERO-2,4-OXAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SRD5A2, PPARD, SRD5A1 SMN1; SMN2 2291/4885TSHR 790/4885CASP1 3034/4885
US-20060058553-A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase HDAC1, HDAC2, HDAC11 SMN1; SMN2 2943/4885TSHR 3583/4885CASP1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.